Agenus Inc. (AGEN) Expected to Post FY2020 Earnings of ($1.17) Per Share
Agenus Inc. (NASDAQ:AGEN) – Research analysts at William Blair issued their FY2020 earnings estimates for Agenus in a report released on Monday. William Blair analyst J. Sonnier forecasts that the biotechnology company will earn ($1.17) per share for the year.
Other equities research analysts have also recently issued research reports about the stock. Maxim Group restated a “buy” rating and issued a $7.00 target price on shares of Agenus in a report on Sunday, April 23rd. HC Wainwright set a $5.00 target price on shares of Agenus and gave the stock a “hold” rating in a report on Saturday, May 6th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and three have given a buy rating to the company’s stock. The company currently has an average rating of “Hold” and an average target price of $6.33.
Agenus (NASDAQ AGEN) traded down 2.23% during midday trading on Tuesday, hitting $3.95. 421,530 shares of the company were exchanged. The stock has a 50 day moving average of $3.55 and a 200-day moving average of $3.87. Agenus has a 1-year low of $3.20 and a 1-year high of $7.49. The stock’s market capitalization is $391.52 million.
Agenus (NASDAQ:AGEN) last posted its quarterly earnings results on Thursday, May 4th. The biotechnology company reported ($0.18) EPS for the quarter, topping analysts’ consensus estimates of ($0.32) by $0.14. The company had revenue of $26.96 million for the quarter, compared to analysts’ expectations of $5.22 million. Agenus had a negative net margin of 257.79% and a negative return on equity of 37,577.49%.
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in AGEN. Oracle Investment Management Inc. acquired a new position in Agenus during the first quarter valued at $6,444,000. State Street Corp increased its position in Agenus by 64.3% in the fourth quarter. State Street Corp now owns 3,502,274 shares of the biotechnology company’s stock valued at $14,430,000 after buying an additional 1,370,515 shares during the last quarter. Goldman Sachs Group Inc. increased its position in Agenus by 3,447.2% in the first quarter. Goldman Sachs Group Inc. now owns 673,333 shares of the biotechnology company’s stock valued at $2,539,000 after buying an additional 654,351 shares during the last quarter. Marshall Wace LLP acquired a new position in Agenus during the fourth quarter valued at $2,044,000. Finally, MARSHALL WACE ASIA Ltd acquired a new position in Agenus during the first quarter valued at $1,561,000. Institutional investors and hedge funds own 42.61% of the company’s stock.
In other Agenus news, CEO Garo H. Armen purchased 100,000 shares of the firm’s stock in a transaction on Wednesday, April 12th. The shares were acquired at an average cost of $3.35 per share, for a total transaction of $335,000.00. Following the completion of the transaction, the chief executive officer now owns 1,389,021 shares of the company’s stock, valued at $4,653,220.35. The acquisition was disclosed in a filing with the SEC, which is accessible through the SEC website. 7.90% of the stock is currently owned by company insiders.
Agenus Inc (Agenus) is an immuno-oncology (I-O) company. The Company focuses on the discovery and development of therapies that engage the body’s immune system to fight cancer. It is developing a I-O portfolio driven by platforms and programs, such as antibody discovery platforms, including Retrocyte Display, SECANT yeast display and phage display technologies designed to produce human antibodies; antibody candidate programs, including checkpoint modulator (CPM) programs; vaccine programs, including Prophage, AutoSynVax and PhosPhoSynVax, and saponin-based vaccine adjuvants, principally QS-21 Stimulon adjuvant (QS-21 Stimulon).
Receive News & Ratings for Agenus Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agenus Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.